Momentum Rank : 19.62 Indicates weak momentum, suggesting underperformance relative to the market
This triple mechanism distinguishes retatrutide from existing approved weight loss peptides such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist), although direct head-to-head trials comparing these agents have not been conducted, and comparative efficacy has not been established
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H , Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B
But then, a less pleasant side effect appears: diarrhea
Stimulants cause tolerance development, meaning increasing doses are needed for the same effect